NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
Navigating Economic Resilience Through Life Sciences Investment
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Equity-Based Pricing: Enhancing Value in Primary Care through Socioeconomic C...
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...